Attached files
| file | filename |
|---|---|
| EX-99.1 - EXHIBIT 99.1 - PDS Biotechnology Corp | s001746x1_ex99-1.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): June 8, 2017
Edge Therapeutics, Inc.
(Exact name of Registrant as specified in its charter)
|
Delaware
|
001-37568
|
26-4231384
|
|
(State or Other Jurisdiction of Incorporation or Organization)
|
(Commission File Number)
|
(I.R.S. Employer Identification No.)
|
300 Connell Drive, Suite 4000
Berkeley Heights, NJ 07922
(800) 208-3343
(Address, Including Zip Code, and Telephone Number, Including Area Code, of Registrant’s Principal Executive Offices)
Not Applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
☐
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17CFR 240.14a-12)
|
|
☐
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
☐
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
|
ITEM 8.01.
|
Other Events.
|
On June 8, 2017, Edge Therapeutics, Inc. issued a press release announcing that it received a product-specific pediatric waiver from the European Medicines Agency for its lead product candidate, EG-1962, which is currently in Phase 3 clinical development for the treatment of aneurysmal subarachnoid hemorrhage. A copy of the press release is filed herewith as Exhibit 99.1.
|
ITEM 9.01.
|
Financial Statements and Exhibits.
|
(d) Exhibits.
|
Exhibit
|
Description
|
|
|
99.1
|
Press release dated June 8, 2017.
|
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
Date: June 9, 2017
|
Edge Therapeutics, Inc.
|
|
|
/s/ Albert Marchio
|
||
|
Name:
|
Albert Marchio
|
|
|
Title:
|
Chief Accounting and Administrative Officer, Interim Chief Financial Officer
|
|
Index to Exhibits
|
Exhibit
|
Description
|
|
|
99.1
|
Press release dated June 8, 2017.
|